Kardigan completes enrollment in Phase 2b aortic stenosis trial
Kardigan Inc. (NASDAQ:KARD) completed enrollment in its Phase 2b KATALYST-AV trial for ataciguat, enrolling 156 participants. The protocol was amended to assess aortic valve calcium at Week 48. Baseline data showed varying levels of aortic valve calcium and related conditions. Topline data is expected in late 2027. The company also presented findings from a retrospective analysis of aortic stenosis progression.
How this was made
The 30-second read
Why it matters
The enrollment completion removes a key development risk and sets the stage for interim and final data readouts, which could materially affect valuation.
Market read
First‑report trial milestone for a US‑listed biotech; likely to generate short‑term buying interest ahead of data releases.
What to watch
Potential competition from other soluble guanylate cyclase activators and the need for FDA clearance could temper upside.
Background
Kardigan is a clinical‑stage biotech developing ataciguat for aortic stenosis, an area with unmet medical need.
Ticker impact
Kardigan announced completion of enrollment in its Phase 2b KATALYST-AV trial for ataciguat in aortic stenosis patients.
upward pressure as investors price in the trial advancement and upcoming data readout.
The news is the first public disclosure of enrollment completion, a material clinical‑trial milestone for a biotech with a US listing.
Market effects
May boost sentiment for the broader cardiovascular‑device and biotech sector as trial pipelines advance.
Limited to US biotech investors; no broader regional effect.
Modest global relevance, primarily affecting investors tracking clinical‑trial milestones.
Counterpoint
If the trial later shows limited efficacy, the early enrollment news could be a short‑term hype that fades.
Key entities
- companyKardigan Inc.
NASDAQ‑listed biotech developing ataciguat.
- partnerSanofi
Licensor of the ataciguat molecule.
